// App-Quantinova.ai

DMT43 : Ponesimod in Relapsing Forms of Multiple Sclerosis - Long-Term Pooled Safety Results from the Clinical Development Program

Researchers

Presenter

  • Mauricio Rosas-Ballina

Principal Investigators

  • Annette Wooller

  • Verena Walter

  • Maria Ait-Tihyaty

  • Andrea Vaclavkova

  • Carlo Pozzilli

Medical Centers

  • Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies, Allschwil, Switzerland

  • Janssen Medical Affairs, Janssen-Cilag Ltd, High Wycombe, UNITED KINGDOM

  • Department of Human Neuroscience, Sapienza University of Rome Roma Italy

Locations

  • Switzerland

  • Italy

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • Ponesimod

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved